































(International Journal of Antimicrobial Agents 45 (2015) 564–567
Contents lists available at ScienceDirect
International  Journal  of  Antimicrobial  Agents
jo ur nal ho me  pag e: h t tp : / /www.e lsev ier .com/ locate / i jant imicag
eview
oes  use  of  the  polyene  natamycin  as  a  food  preservative  jeopardise
he  clinical  efﬁcacy  of  amphotericin  B?  A  word  of  concern
xel  A.H.  Dalhoffa,∗, Stuart  B.  Levyb
University Medical Center Schleswig-Holstein, Institute for Infection Medicine, Brunswiker Str. 4, D-24105 Kiel, Germany
Center for Adaptation Genetics and Drug Resistance, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA  02111, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 23 February 2015






a  b  s  t  r  a  c  t
Natamycin  is  a poorly  soluble,  polyene  macrolide  antifungal  agent  used  in  the  food  industry  for  the
surface  treatment  of cheese  and  sausages.  This  use  is  not  of  safety  concern.  However,  highly  soluble
natamycin–cyclodextrin  inclusion  complexes  have  been  developed  for  the protection  of  beverages.  This
practice  leads  to high  drug  exposures  exceeding  the  safety  level.  Apart  from  the  deﬁnition  of an acceptable
daily  dietary  exposure  to natamycin,  its effect  on  the  faecal  ﬂora  as  a reservoir  for  resistance  has  to  be
examined.  Consumption  of food  to which  natamycin  has  been  added  and mixed  homogeneously,  such
as  yoghurt,  and in  particular  the  addition  of cyclodextrin  inclusion  complexes  to  beverages  and  wine
generates  high  faecal  natamycin  concentrations  resulting  in  high  drug  exposures  of faecal  Candida  spp.
Development  of  natamycin  resistance  has been  observed  in  Candida  spp.  colonising  the intestinal  tract
of  patients  following  natamycin  treatment  of  fungal  infections.  Horizontal  gene  transfer  among  different
Candida  spp.  and  within  Aspergillus  fumigatus  spreads  resistance.  Therefore,  it cannot  be denied  that  use
of natamycin  for  preservation  of  yoghurt  and  beverages  may  foster  development  of  resistance  to polyenes
in Candida  spp.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  on  behalf  of  International  Society of  Chemotherapy.
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. Introduction
Natamycin is a member of the polyene macrolide class of anti-
nfectives (in the following ‘polyene’). Natamycin shows in vitro
ctivity against yeasts and ﬁlamentous fungi such as Candida spp.,
spergillus spp., Cephalosporium spp., Fusarium spp. and Penicil-
ium spp. but is inactive against Gram-positive and Gram-negative
erobic and anaerobic bacteria [1]. In addition, it is useful in the
reatment of human disease and in the protection of foods.
Natamycin is given to humans for the topical treatment of fungal
ye, mouth, skin and vaginal infections. Other polyene antifun-
als applied in human medicine are amphotericin B and nystatin.
hilst nystatin is useful for the prevention or treatment of minor
ungal infections such as oropharyngeal or vaginal Candida infec-
ions, amphotericin B is used to treat serious life-threatening fungal
nfections.The food industry employs natamycin for the preservation of
heese, sausages, yoghurt and, in some countries, juices and wine.
atamycin is preferable to many other preservatives as it is free
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from odour and colour so that it causes no taste aversion and
therefore does not adversely affect consumer acceptance. It resists
dissolving in water so it is not easily removed by washing, thus
maintaining its activity as a preservative. Natamycin is extremely
sensitive to ultraviolet (UV) light [2]. Cheese products are exposed
to light in the retail dairy industry, thus natamycin treatment on the
products is likely degraded by the time of purchase by the consumer
[3]. Even if the surface of these products may not be removed or if
natamycin may  not be inactivated by UV light, the estimated dietary
exposure to natamycin is ten times lower than the acceptable daily
intake (ADI) level deﬁned by the Joint Food and Agriculture Organi-
zation of the United Nations and World Health Organization Expert
Committee on Food Additives (JECFA). Therefore, natamycin for the
surface treatment of cheese and sausages can be regarded as safe
for human use [4].
However, recent concern is being raised regarding the use of
natamycin as an additive to beverages and yoghurt, as gastroin-
testinal Candida spp. may  be exposed to high drug concentrations,
hypothetically exerting a resistance selective pressure. The risks
associated with the use of anti-infectives by the food industry are
discussed controversially, but antibiotic use in veterinary medicine
and for growth promotion and disease prevention in agriculture,
aquaculture and horticulture is also a major contributing factor to
resistance development [5].
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Addition of natamycin to food is different from the use of
nti-infectives in veterinary medicine. In the latter instance, antibi-
tic resistance genes of microbial origin may  be transferred from
reated animals to human beings via the food chain and/or con-
umption of contaminated food, whilst the use of natamycin as
 food additive may  expose the human intestinal ﬂora directly
o the selective pressure. This review summarises the evidence
hat preservation of yoghurt with natamycin and the probable
se of novel water-soluble natamycin formulations for the preser-
ation of beverages may  exert a resistance selective pressure on
he gastrointestinal fungal ﬂora, hypothetically jeopardising the
fﬁcacy of polyenes as a class of life-saving antifungal human
gents.
. Pharmacology of natamycin
Apart from its low water solubility and instability to UV light,
atamycin decomposes at the extremes of pH. Degradation of
atamycin in an acidic medium, as occurs in beverage products,
ields mycosamine and three degradation products all containing
n intact lactone ring; the degradation products are considered to
e inactive [6,7]. In principle, these characteristics may  be advan-
ageous for the use of natamycin in the production of solid food.
owever, the limited water solubility of natamycin is doubly dis-
dvantageous; ﬁrst, the dissolved fraction only diffuses to the site
f action, so that low solubility is a limiting factor in the antifungal
ctivity of natamycin [2]; and second, natamycin is not sufﬁciently
oluble in beverages to function as a beverage preservative in
nd of itself [8]. The highest achievable natamycin concentration
n beverages is 52 mg/L, a concentration four-fold less than the
mount needed to prohibit outgrowth of fungi for a period of 16
eeks, the limit of product shelf-life [8]. Therefore, natamycin has
een formulated as a cyclodextrin inclusion complex. Cyclodex-
rins act as host molecules to form inclusion complexes with guest
olecules. The cyclodextrin molecule can at least partially shield
he guest molecule from degradation caused by light, oxidation,
eat, and acidic or alkaline conditions [9]. Cyclodextrins not only
nsulate labile compounds from a potentially corrosive environ-
ent, they also increase solubility of poorly soluble agents [8,10].
nclusion of natamycin into cyclodextrin permits the preparation
f a complex containing 500 mg/L of solubilised natamycin and
rotects natamycin from inactivation in an acidic environment as
revailing in beverages. Consequently, the natamycin–cyclodextrin
omplex remained stable for 16 weeks of storage in the dark
8,10].
It is important to note that inclusion of natamycin into cyclodex-
rin left the antifungally active moiety of the natamycin molecule,
.e. the mycosamine group, intact and freely accessible. Ergosterol
inding via the mycosamine group represents the ﬁrst and deci-
ive reaction required for antifungal action; the lactone ring of
olyenes inserts into the lipid bilayer of fungi [1,11,12]. In addition
o ergosterol binding, natamycin impairs membrane fusion via per-
urbation of ergosterol-dependent priming reactions that precede
embrane fusion.
Considering the increased solubility of natamycin–cyclodextrin
omplexes and chemical structures being relevant for its mode
f action, theoretically increased solubility is followed by
ncreased antifungal activity, and decomposition to mycosamine-
nd/or lactone ring-containing products should yield degra-
ation products still being antifungally active. Both theories
ave been conﬁrmed. Natamycin–cyclodextrin complexes are
pproximately twice as active as natamycin itself and degra-
ation products have been characterised that have retained
5%, 46% and 14% of the activity of the intact molecule
6,10].f Antimicrobial Agents 45 (2015) 564–567 565
3. Dietary exposure to natamycin following consumption
of natamycin-containing beverages or yoghurt
Given that natamycin is ‘very poorly absorbed’ from the gas-
trointestinal tract, and based on several toxicological studies in
animals and a clinical study performed in humans, JECFA estab-
lished in 1968 an acceptable daily intake (ADI) of 0.3 mg/kg body
weight per day (i.e. 18 mg  per adult weighing 60 kg), which was
conﬁrmed in 2002 by JECFA [4,13]. It is essential to indicate that
the classiﬁcation of natamycin as being ‘very poorly absorbed’ is
based on a review article published by Brik [6], who referred to a
study performed by Lynch et al. [14] published in 1961. Natamycin
serum concentrations were quantitated biologically. Eight patients
were dosed with 125–500 mg  of natamycin per day. Eleven sam-
ples were withdrawn at non-speciﬁed time points. The frequency of
dosing and allocation of patients to dose groups was not speciﬁed.
Serum concentrations below the limit of detectability of 3.8 mg/L
were recorded under these experimental conditions. The use of bio-
logical methods for drug quantitation was  adequate and standard
50 years ago, but the design and analytical methods of the study
are suboptimal based on present capabilities.
It is also important to note that the JECFA decision is based
on studies that have been performed with the almost insolu-
ble natamycin and not with the soluble natamycin–cyclodextrin
inclusion complex. Data on the pharmacokinetics and toxico-
logy of natamycin–cyclodextrin inclusion complexes have not yet
been published. The increased solubility of cyclodextrin inclu-
sion complexes of a drug can increase its dissolution rate, so that
increased oral bioavailability is achieved for agents that are oth-
erwise non-absorbable [15]. For example, the bioavailability of
itraconazole and its metabolite hydroxyl-itraconazole could be
enhanced by 30–37% following oral administration of cyclodex-
trin inclusion complexes compared with the conventional capsule
[16]. Thus, natamycin could hypothetically be absorbed from the
gastrointestinal tract following oral administration of a soluble
natamycin–cyclodextrin inclusion complex; absorbed natamycin
could hypothetically expose organ systems relevant for toxico-
logical examinations to higher drug concentrations than studied
previously. Even if this scenario is speculative, the hypothesis mer-
its further study.
The solubility of natamycin in apple juice is 20 mg/L at 25 ◦C and
pH 3.4 and 10 mg/L at 4 ◦C and pH 3.4 [8]. Consumption of 1 L of
apple juice containing either 10 mg  or 20 mg natamycin by an adult
human consumer weighing 60 kg results in a dietary exposure cor-
responding to 50% and 111% of the ADI level. However, a use level
of 8.33 mg/kg body weight/day would result from the consumption
of the maximally soluble fraction of natamycin–cyclodextrin inclu-
sion complex of 500 mg/L, so that the ADI level will be exceeded
27.8-fold.
Yoghurt products containing 5–10 mg  natamycin/kg are com-
mercially available in South Africa, Canada and China and may be
available in the USA in due course. Consumption of such prepara-
tions may  result in an estimated 2-day daily intake of natamycin
from background and proposed uses for the total US population of
0.61–1.22 mg/day [17], which is clearly below the ADI  level.
But more importantly, faecal Candida spp. will be exposed to
relatively high natamycin concentrations, which may  hypotheti-
cally trigger the development of polyene resistance. Assuming ﬁrst
a daily production of faeces of 150 g by an adult Caucasian, and
assuming second that the entire amount of natamycin consumed
with beverages or yoghurt is deposited in the faeces, faecal con-
centrations of natamycin may  range from 3.33 mg/kg following
consumption of 100 g of yoghurt containing 5 ppm to 3333.0 mg/kg
following consumption of 1 L of beverage containing the maximally
soluble concentration of 500 mg  of natamycin. Assuming third that
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ctive, even the lowest faecal concentration of natamycin exceeds
he minimum inhibitory concentrations (MICs) for Candida albicans
nd Saccharomyces cerevisiae ranging from 1.1 mg/L to 2.6 mg/L
6,10], so that faecal natamycin concentrations may  exert a selec-
ive pressure on the resident ﬂora. Thus, there is concern that
atamycin may  have a propensity for drug resistance selection.
. Natamycin resistance development in environmental
ungi
Natamycin has been used for almost three decades for the
reservation of cheese and sausages. Surveys in cheese warehouses
nd in dry sausage factories where natamycin had been used for up
o 9 years showed no change in the composition or sensitivity of
he contaminating fungal ﬂora [18–21].
In vitro exposure of strains isolated from cheese warehouses
o increasing natamycin concentrations revealed that after 25–30
ransfers none of the strains had become less sensitive to natamycin
18].
Based on these data [18–21] and the fact that natamycin is not
ctive against bacteria, the European Food Safety Authority (EFSA)
anel concluded that there was no concern for the induction of
ntimicrobial resistance. However, the panel did not assess the
ffect of natamycin on the resident human ﬂora.
. Resistance development of the resident ﬂora to polyenes
The human resident microﬂora acts as a barrier against
olonisation by potentially pathogenic micro-organisms [22–27].
mergence of resistance among the resident microﬂora and dis-
ribution of resistance genes by transfer of DNA in the microbial
ommunity can contribute to an increased load of resistant, poten-
ially pathogenic micro-organisms. Another effect of a disturbed
ormal microﬂora is a reduction in colonisation resistance, leading
o overgrowth of already present or exogenous micro-organisms
22–27].
Since C. albicans lacks any apparent environmental reservoir, it
enerally grows in association with a mammalian host, where it
s a very effective coloniser. Candida albicans is commonly found
s a component of the normal ﬂora of humans, residing in the
astrointestinal and genitourinary tracts and on the skin [28–30].
olonising organisms are thought to be benign, but they may  cause
ife-threatening infections in an immunocompromised host such as
he elderly, transplant recipients, or patients with cancer or human
mmunodeﬁciency virus (HIV). Resistance development is of par-
icular concern in these patients. Only agents of the polyene class
emained effective as fungal resistance to azoles, candins and 5-
uorocytosine and multidrug resistance increased worldwide, so
hat the authors of a recent review article conclude that ‘the rapid
evelopment of antifungal resistance, the toxicity and the variabil-
ty in available formulations of some agents, and the increase in
he frequency of non-albicans Candida spp. infections support the
eed for more effective and less toxic treatment strategies’ [31].
his statement underscores the high clinical relevance to maintain
he efﬁcacy of the polyenes.
It is therefore important to analyse the effect of any antimi-
robial agent on the resident ﬂora. In the context of the use of
atamycin as a food antimicrobial, it has to be determined whether
olyenes in general or natamycin in particular may  deteriorate the
usceptibility pattern of colonising Candida spp. Development of
esistance to natamycin has been observed. Natamycin has been
iven orally for the treatment of intestinal candidosis at a daily
ose of 400 mg  for 10 days to 356 patients [32]. The drug sus-
eptibility pattern of Candida spp. isolated before, during and after
herapy with natamycin changed signiﬁcantly. Strains with an MICf Antimicrobial Agents 45 (2015) 564–567
of 1.25 mg/L were isolated from 56% of these patients prior to, 33%
during, 51% at 5 days after and 60% at 3 months after therapy [32].
A signiﬁcant reduction in susceptibility to natamycin was observed
during exposure to this agent; the susceptibility pattern returned
to baseline levels during the post-exposure phase. Thus, the loss
of susceptibility of Candida spp. is a drug exposure-related effect.
Strains isolated from women with vaginal candidosis also showed
decreased susceptibility following natamycin treatment. The MICs
of natamycin for Candida spp. increased from 2.9–31 mg/L for
strains isolated from untreated women to 9.8–64 mg/L for strains
from treated women  [33].
Amphotericin resistance has been detected in Candida spp. caus-
ing invasive diseases [34–36]. A recent analysis of Aspergillus spp.
isolated from patients with haematological malignancies revealed
that 25% of the strains studied were characterised by MICs above the
epidemiological cut-off value of 4 mg/L. Thus, the ﬁndings strongly
suggest that these isolates have acquired resistance to ampho-
tericin B [37].
These reports demonstrate that, although rare, polyene resis-
tance amongst human clinical isolates of pathogenic Candida spp. as
well as amongst Candida spp. colonising the human intestinal tract
have acquired polyene resistance. Loss of natamycin susceptibility
upon oral administration of natamycin is of particular concern as
this ﬁnding demonstrates that short-term exposure of Candida spp.
residing in the gut can cause resistance development.
6. Horizontal gene transfer (HGT) creating a threat to
human health
HGT is deﬁned as the exchange of genes either within one
species or between different species. HGT is a major force in
microbial evolution and a great source of genetic innovation in
prokaryotes [38]. In comparison with prokaryotes, HGT  is thought
to occur much less frequently in eukaryotes. The phenomenon of
HGT in fungi is exciting in so far as fungi are the most recalcitrant
of all micro-organisms to transfer genes, possessing robust cell
walls and having lost phagotrophic capacities. None the less, inter-
fungal and intrafungal species HGT has been described. HGT  has
also proved to be a factor in the evolution of eukaryotic genomes,
enabling fungi to colonise additional environments or to spread
resistance (reviewed in [39]). Thus, HGT among different Candida
spp. and within Aspergillus fumigatus has contributed to pathoad-
aptive responses such as bioﬁlm formation and also to the spread of
polyene and azole resistance. Consequently, it cannot be excluded
that consumption of natamycin-containing beverages or yoghurt
may  in theory prime intestinal yeasts to acquire polyene resis-
tance. This resistance may  spread horizontally and vertically among
colonising Candida spp. and may  disseminate to infectious sites,
putting the patient, in particular the immunocompromised patient,
at risk.
7. Open questions
Natamycin was  discovered and developed more than 50 years
ago. Studies were performed to characterise the toxicological and
pharmacokinetic proﬁle and mirror the methods applied and the
study designs used in those times. Furthermore, natamycin has
been developed for surface treatment of solid food and topical
administration in human medicine. Consequently, a broadened use
of natamycin in food production, such as addition to beverages or
yoghurt, and the development of a new soluble formulation has
never been considered before. In contrast to the use of natamycin
for surface treatment of solid food, its use in liquid and semi-solid
food inevitably exposes the faecal ﬂora to natamycin. This effect
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Assessment of the pharmacokinetics of natamycin and in partic-
ular its cyclodextrin inclusion complex.
Quantitation of total and free faecal natamycin concentrations at
different times following drug ingestion.
Effect of natamycin and its cyclodextrin inclusion complex on the
resident human microﬂora for relevant periods of time.
Monitor polyene resistance development among the human res-
ident fungal ﬂora.
Re-assessment of the antifungal activity of natamycin degrada-
tion products.
. Conclusions
Use of natamycin by the food industry for the surface treat-
ent of solid food is considered to be safe. If at all measurable,
atamycin concentrations are much lower than the ADI level.
ikewise, use of natamycin as a preservative in the production
f semi-solid food such as yoghurt is safe in so far as the daily
ntake of natamycin is much lower than the ADI level. However,
atamycin concentrations in the faeces may  exert a polyene resis-
ance selective pressure, so that faecal Candida spp. may  harbour
nd spread polyene resistance, hypothetically putting elderly and
mmunocompromised patients at risk. This risk will be enhanced
y the consumption of soluble natamycin–cyclodextrin inclusion
omplex-containing beverages or wine as these products contain
igh natamycin concentrations with higher potential to exert prob-
bly a strong selective pressure on the emergence of resistance in
aecal Candida spp. Importantly, the risks associated with the use of
atamycin in semi-solid food or the use of natamycin–cyclodextrin
nclusion complexes cannot be assessed until questions regarding
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